Compare ELMT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMT | EOLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | 350 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.9M | 384.6M |
| IPO Year | 2026 | 2018 |
| Metric | ELMT | EOLS |
|---|---|---|
| Price | $13.91 | $5.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 360.0K | ★ 712.3K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $12.49 | $3.86 |
| 52 Week High | $20.91 | $9.35 |
| Indicator | ELMT | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 39.30 |
| Support Level | N/A | $5.45 |
| Resistance Level | $16.23 | $7.16 |
| Average True Range (ATR) | 0.99 | 0.31 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 26.03 | 31.91 |
The Elmet Group Co provides precision-engineered components and high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The company is organized into two business divisions, Critical Materials Components and Engineered Microwave Products, offering a platform with expertise across interconnected markets. The company operates an integrated engineering-to-production system, covering custom design, development, and processing across Critical Materials and High-Power Microwave. Its Engineered Microwave capabilities helps to deliver tailored microwave energy solutions, while its Critical Materials expertise allows to design reliable solutions for some of the demanding environments in the world.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.